Michelle Rheault, MD
banner
rheaultm.bsky.social
Michelle Rheault, MD
@rheaultm.bsky.social
Ped nephrologist, Division director, #NephJC, MN girl, COI: several. Alis volat propriis. Breast cancer survivor, Pronounced “row”, (she/her). Bluesky is not a dating app.
Turned out ok!
November 28, 2025 at 1:29 AM
Interesting. We see the same pattern when you cross into the pediatric population. Girls have higher mortality. Doesn’t make sense to me. pmc.ncbi.nlm.nih.gov/articles/PMC...
November 26, 2025 at 1:11 AM
Reposted by Michelle Rheault, MD
Nephrology wasn’t a planned choice for me, but with time I genuinely fell in love with it.
November 24, 2025 at 1:41 AM
We’ve got balcony tickets with all the old people where we can listen to music like god intended—sitting down!
November 23, 2025 at 2:40 AM
Of course, that would require that anyone in the government cared about child health, so won’t happen anytime soon.
November 21, 2025 at 2:22 PM
What this means is that the government has a potential lever to push companies to complete their pediatric studies. For example, if pediatric studies are delayed then Medicare reimbursement for that drug could progressively be reduced.
November 21, 2025 at 2:22 PM
This study looked at new FDA approved drugs from 2015 to 2021. Of these, 38% hadn’t completed their PREA requirements within 5 years. They also estimate that the US government spent 27 billion dollars on all newly approved drugs during that timeframe.
November 21, 2025 at 2:22 PM
In the US, the pediatric research equity act (PREA) requires companies to perform pediatric studies for relevant new drugs. These often occur after commercial approval and many are never completed by the companies, leaving pediatricians to guess about dosing and safety.
November 21, 2025 at 2:22 PM
It’s embarrassing.
November 20, 2025 at 2:21 AM